Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.32 |
| ▸ | ELANE | P08246 | 3/20 | 0.32 |
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | EDNRB | P24530 | 1/20 | 0.30 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20848951 | 0.99 | AR (0.32) | ARELANEKIF11CYP2C9SCN9A | |
| SCHEMBL22985479 | 0.95 | KIF11 (0.34) | ARELANEKIF11CYP2C9SCN9A | |
| SCHEMBL20848908 | 0.95 | KIF11 (0.36) | ARELANEKIF11PDPK1 | |
| SCHEMBL20848492 | 0.94 | ALOX5AP (0.33) | ARKIF11SCN9AALOX5APFEN1 | |
| SCHEMBL22985138 | 0.94 | AR (0.34) | ARKIF11CYP2C9SCN9AALOX5AP | |
| SCHEMBL20849190 | 0.94 | KIF11 (0.33) | ARKIF11SCN9APDPK1 | |
| SCHEMBL20848966 | 0.94 | KIF11 (0.33) | ARELANEKIF11SCN9A | |
| SCHEMBL20848810 | 0.94 | KIF11 (0.33) | ARELANEKIF11SCN9A | |
| SCHEMBL20849075 | 0.94 | KIF11 (0.33) | ARELANEKIF11SCN9A | |
| SCHEMBL20849074 | 0.94 | KIF11 (0.33) | ARELANEKIF11SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919880-B2 | Organic molecules, in particular for use in optoelectronic devices | CYNORA GMBH (DE) | 2021-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919880-B2 | Organic molecules, in particular for use in optoelectronic devices | OCIAD1, OCIAD2, POU2F1 | AR 3541/4885ELANE 3847/4885KIF11 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.